Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 83Neoplasm Metastasis 10Neoplasms 6Prostatic Neoplasms, Castration-Resistant 5Carcinoma, Non-Small-Cell Lung 4Metastatic Castration-Resistant Prostate Cancer 3Colorectal Neoplasms 3Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, Non-Hodgkin 2Castration-resistant Prostate Cancer 2Carcinoma, Hepatocellular 2Bulbo-Spinal Atrophy, X-Linked 2Breast Neoplasms 2Bites and Stings 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Solid Tumours 1Salivary Gland Neoplasms 1

Interventions

apalutamide 1abiraterone 1Radiosurgery 1Leuprolide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Newly Diagnosed Oligometastatic Prostate Cancer × abiraterone × Clear all
NCT03298087 2025-08-01

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

VA Office of Research and Development

Phase 2 Completed
28 enrolled 10 charts
Genitourinary

Newly Diagnosed Oligometastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡